BPG is committed to discovery and dissemination of knowledge
Featured Articles
9/22/2023 12:33:15 PM | Browse: 155 | Download: 352
 |
Received |
|
2023-06-08 03:54 |
|
Peer-Review Started |
|
2023-06-08 03:55 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-08-07 02:50 |
|
Revised |
|
2023-08-21 02:26 |
|
Second Decision |
|
2023-09-14 02:53 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-09-14 08:57 |
|
Articles in Press |
|
2023-09-14 08:57 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-09-19 07:37 |
|
Publish the Manuscript Online |
|
2023-09-22 12:27 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Baseline metabolites could predict responders with hepatitis B virus-related liver fibrosis for entecavir or combined with FuzhengHuayu tablet
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yun-Kai Dai, Hai-Na Fan, Kai Huang, Xin Sun, Zhi-Min Zhao and Cheng-Hai Liu |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Science and Technology Major Project |
No. 2014ZX10005001 and No.2018ZX10302204 |
| National Natural Science Foundation of China |
No. 81730109 and No. 82274305 |
| Shanghai Key Specialty of Traditional Chinese Clinical Medicine |
No. shslczdzk01201 |
| China Postdoctoral Science Foundation |
No. 2022M722162 |
| Siming Youth Fund of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine |
No. SGKJ-202104 |
|
| Corresponding Author |
Cheng-Hai Liu, MD, PhD, Director, Doctor, Professor, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine and Shanghai Key Laboratory of Traditional Chinese Clinical Medicine and Key Laboratory of Liver and Kidney Diseases, Institute of Liver Diseases, No. 528 Zhangheng Road, Pudong New Area, Shanghai 201203, China. chenghai.liu@shutcm.edu.cn |
| Key Words |
Serum metabolomics; Differential metabolites; Therapeutic responders; entecavir; FuzhengHuayu tablet; Hepatitis B virus-related liver fibrosis |
| Core Tip |
This study will use high-performance liquid chromatography-tandem mass spectrometry and multivariate statistical modelings to predict serum metabolites of the treatment (entecavir or entecavir + FuzhengHuayu tablet) that effectively reversed hepatitis B virus-related liver fibrosis. It is of great theoretical and practical significance to prevent the transformation of liver fibrosis to cirrhosis or even hepatocellular carcinoma and reduce the social burden. |
| Publish Date |
2023-09-22 12:27 |
| Citation |
Dai YK, Fan HN, Huang K, Sun X, Zhao ZM, Liu CH. Baseline metabolites could predict responders with hepatitis B virusrelated liver fibrosis for entecavir or combined with FuzhengHuayu tablet. World J Hepatol 2023; 15(9): 1043-1059 |
| URL |
https://www.wjgnet.com/1948-5182/full/v15/i9/1043.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v15.i9.1043 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
